{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:53Z","timestamp":1793228273106,"version":"4.5.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0233781","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T17:32:50Z","timestamp":1590600770000},"page":"e0233781","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":55,"title":["Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":true,"given":"Johan","family":"Burisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Eigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"6","key":"pone.0233781.ref001","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"F Magro","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"1","key":"pone.0233781.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"F Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7422","key":"pone.0233781.ref003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"L Jostins","year":"2012","journal-title":"Nature"},{"issue":"7","key":"pone.0233781.ref004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"WQ Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"pone.0233781.ref005","article-title":"Incidence and risk of inflammatory bowel disease in patients with psoriasis\u2014a nationwide 20-year cohort study","author":"A Egeberg","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"pone.0233781.ref006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","article-title":"A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis","volume":"19","author":"E Klingberg","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"pone.0233781.ref007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"C Gu","year":"2013","journal-title":"Cytokine"},{"issue":"4","key":"pone.0233781.ref008","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"RG Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"9993","key":"pone.0233781.ref009","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"CE Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"9999","key":"pone.0233781.ref010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"IB McInnes","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"pone.0233781.ref011","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"D Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0233781.ref012","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"M Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0233781.ref013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"A Ogawa","year":"2004","journal-title":"Clin Immunol"},{"issue":"4","key":"pone.0233781.ref014","first-page":"739","article-title":"Differential Roles for Interleukin-23 and Interleukin-17","volume":"43","author":"JR Maxwell","year":"2015","journal-title":"Intestinal Immunoregulation. Immunity"},{"issue":"12","key":"pone.0233781.ref015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"W Hueber","year":"2012","journal-title":"Gut"},{"issue":"11","key":"pone.0233781.ref016","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease","volume":"111","author":"SR Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"pone.0233781.ref017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"M Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"pone.0233781.ref018","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","article-title":"Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials","volume":"76","author":"K Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"pone.0233781.ref019","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","author":"S Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"pone.0233781.ref020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"JO Friedrich","year":"2007","journal-title":"BMC medical research methodology"},{"key":"pone.0233781.ref021","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011 [Available from: http:\/\/handbook.cochrane.org."},{"issue":"7109","key":"pone.0233781.ref022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ (Clinical research ed)"},{"key":"pone.0233781.ref023","volume-title":"Computer program","author":"Review Manager (RevMan)","year":"2014"},{"key":"pone.0233781.ref024","unstructured":"Team RC. R: A Language and Environment for Statistical Computing 2014 [Available from: http:\/\/www.R-project.org\/."},{"key":"pone.0233781.ref025","doi-asserted-by":"crossref","unstructured":"Schwarzer G. meta: An R package for meta-analysis. R News2007.","DOI":"10.32614\/CRAN.package.meta"},{"issue":"9","key":"pone.0233781.ref026","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"A Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"pone.0233781.ref027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/03009742.2017.1390605","article-title":"Secukinumab after anti-tumour necrosis factor-\u03b1 therapy: a phase III study in active rheumatoid arthritis","volume":"47","author":"E Dokoupilov\u00e1","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"pone.0233781.ref028","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"H Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"pone.0233781.ref029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"U Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"pone.0233781.ref030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"R Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"21","key":"pone.0233781.ref031","first-page":"2102","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"KB Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0233781.ref032","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"A Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"pone.0233781.ref033","article-title":"Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study","author":"C Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"pone.0233781.ref034","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"EV Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"pone.0233781.ref035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"M Rudwaleit","year":"2006","journal-title":"Best practice & research Clinical rheumatology"},{"issue":"5","key":"pone.0233781.ref036","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn's disease","volume":"23","author":"AD Cohen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"pone.0233781.ref037","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"M Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0233781.ref038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial","volume":"76","author":"A Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"pone.0233781.ref039","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","article-title":"Secukinumab in Active Rheumatoid Arthritis after Anti-TNF\u03b1 Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study","volume":"4","author":"H Tahir","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"3","key":"pone.0233781.ref040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3899\/jrheum.130637","article-title":"One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study","volume":"41","author":"MC Genovese","year":"2014","journal-title":"J Rheumatol"},{"issue":"3","key":"pone.0233781.ref041","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3899\/jrheum.150117","article-title":"Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study","volume":"43","author":"W Tlustochowicz","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"pone.0233781.ref042","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study","volume":"69","author":"FJ Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"pone.0233781.ref043","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"MC Genovese","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pone.0233781.ref044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.140831","article-title":"Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis","volume":"43","author":"MC Genovese","year":"2016","journal-title":"J Rheumatol"},{"issue":"5","key":"pone.0233781.ref045","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"DA Martin","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"pone.0233781.ref046","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"K Pavelka","year":"2015","journal-title":"J Rheumatol"},{"issue":"7","key":"pone.0233781.ref047","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/sim.6383","article-title":"Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless","volume":"34","author":"O Kuss","year":"2015","journal-title":"Statistics in medicine"},{"issue":"4","key":"pone.0233781.ref048","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/03610919608813357","article-title":"An assessment of the use of the continuity correction for sparse data in meta-analysis","volume":"25","author":"SS Sankey","year":"1996","journal-title":"Communications in Statistics\u2014Simulation and Computation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T14:09:21Z","timestamp":1722953361000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233781"}},"subtitle":[],"editor":[{"given":"Stefanos","family":"Bonovas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0233781","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}